000272835 001__ 272835
000272835 005__ 20240229162318.0
000272835 0247_ $$2doi$$a10.3390/cells12040589
000272835 0247_ $$2pmid$$apmid:36831256
000272835 0247_ $$2pmc$$apmc:PMC9954512
000272835 0247_ $$2altmetric$$aaltmetric:142931829
000272835 037__ $$aDKFZ-2023-00408
000272835 041__ $$aEnglish
000272835 082__ $$a570
000272835 1001_ $$aKoll, Florestan J$$b0
000272835 245__ $$aOverexpression of KMT9α Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer.
000272835 260__ $$aBasel$$bMDPI$$c2023
000272835 3367_ $$2DRIVER$$aarticle
000272835 3367_ $$2DataCite$$aOutput Types/Journal article
000272835 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677578047_27831
000272835 3367_ $$2BibTeX$$aARTICLE
000272835 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272835 3367_ $$00$$2EndNote$$aJournal Article
000272835 520__ $$aMuscle-invasive bladder cancer (MIBC) is associated with limited response rates to systemic therapy leading to a significant risk of recurrence and death. A recently discovered histone methyltransferase KMT9, acts as an epigenetic regulator of carcinogenesis in different tumor entities. In this study, we investigated the presence and association of histological and molecular subtypes and their impact on the survival of KMT9α in MIBC. We performed an immunohistochemical (IHC) analysis of KMT9α in 135 MIBC patients undergoing radical cystectomy. KMT9α was significantly overexpressed in the nucleus in MIBC compared to normal urothelium and low-grade urothelial cancer. Using the HTG transcriptome panel, we assessed mRNA expression profiles to determine molecular subtypes and identify differentially expressed genes. Patients with higher nuclear and nucleolar KMT9α expression showed basal/squamous urothelial cancer characteristics confirmed by IHC and differentially upregulated KRT14 expression. We identified a subset of patients with nucleolar expression of KMT9α, which was associated with an increased risk of death in uni- and multivariate analyses (HR 2.28, 95%CI 1.28-4.03, p = 0.005). In conclusion, basal-like MIBC and the squamous histological subtype are associated with high nuclear KMT9α expression. The association with poor survival makes it a potential target for the treatment of bladder cancer.
000272835 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000272835 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000272835 650_7 $$2Other$$aMIBC
000272835 650_7 $$2Other$$achemotherapy
000272835 650_7 $$2Other$$ahistone methyltransferase
000272835 650_7 $$2Other$$amolecular subtypes
000272835 7001_ $$00000-0002-1394-1083$$aMetzger, Eric$$b1
000272835 7001_ $$aHamann, Jana$$b2
000272835 7001_ $$aRamos-Triguero, Anna$$b3
000272835 7001_ $$aBankov, Katrin$$b4
000272835 7001_ $$00000-0001-8495-6621$$aKöllermann, Jens$$b5
000272835 7001_ $$aDöring, Claudia$$b6
000272835 7001_ $$aChun, Felix K H$$b7
000272835 7001_ $$0P:(DE-HGF)0$$aSchüle, Roland$$b8
000272835 7001_ $$aWild, Peter J$$b9
000272835 7001_ $$00000-0003-1373-5295$$aReis, Henning$$b10
000272835 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells12040589$$gVol. 12, no. 4, p. 589 -$$n4$$p589$$tCells$$v12$$x2073-4409$$y2023
000272835 909CO $$ooai:inrepo02.dkfz.de:272835$$pVDB
000272835 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-1394-1083$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000272835 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000272835 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000272835 9141_ $$y2023
000272835 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-07T08:42:17Z
000272835 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000272835 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000272835 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000272835 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000272835 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000272835 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2022$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-08-01T15:15:06Z
000272835 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-08-01T15:15:06Z
000272835 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-08-01T15:15:06Z
000272835 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000272835 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELLS-BASEL : 2022$$d2023-10-26
000272835 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000272835 980__ $$ajournal
000272835 980__ $$aVDB
000272835 980__ $$aI:(DE-He78)FR01-20160331
000272835 980__ $$aUNRESTRICTED